Commentary
Peng Teng, Jianfeng Cai. Using proteomimetics to switch angiogenic signaling[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1534-1535

Using proteomimetics to switch angiogenic signaling
Peng Tenga, Jianfeng Caib
a. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China;
b. Department of Chemistry, University of South Florida, Tampa, FL 33620, USA
Abstract:
Key words:    Proteomimetics    AApeptides    VEGF    VEGFR   
Received: 2022-01-09     Revised: 2022-01-17
DOI: 10.1016/j.apsb.2022.01.016
Corresponding author: Peng Teng,E-mai:pengteng@zju.edu.cn;Jianfeng Cai,E-mai:jianfengcai@usf.edu     Email:pengteng@zju.edu.cn;jianfengcai@usf.edu
Author description:
Service
PDF(KB) Free
Print
0
Authors
Peng Teng
Jianfeng Cai

References:
[1] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646
[2] Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020;5:28
[3] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249
[4] Abdulkadir S, Li C, Jiang W, Zhao X, Sang P, Wei L, et al. Modulating angiogenesis by proteomimetics of vascular endothelial growth factor. J Am Chem Soc 2022;144:270-281
[5] Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009;15:167
[6] Cook KM, Figg WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010;60:222
[7] Ronca R, Benkheil M, Mitola S, Struyf S, Liekens S. Tumor angiogenesis revisited: regulators and clinical implications. Med Res Rev 2017;37:1231
[8] D'Andrea LD, Iaccarino G, Fattorusso R, Sorriento D, Carannante C, Capasso D, et al. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci U S A 2005;102:14215
[9] Basile A, Del Gatto A, Diana D, Di Stasi R, Falco A, Festa M, et al. Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo. J Med Chem 2011;54:1391
[10] Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes. Angew Chem Int Ed 2015;54:8896
[11] Sang P, Shi Y, Huang B, Xue S, Odom T, Cai J. Sulfono-γ-AApeptides as helical mimetics: crystal structures and applications. Acc Chem Res 2020;53:2425
[12] She F, Teng P, Peguero-Tejada A, Wang M, Ma N, Odom T, et al. De novo left-handed synthetic peptidomimetic foldamers. Angew Chem Int Ed 2018;57:9916
Similar articles:
1.Pengzhao Shang, Rui Gao, Yijia Zhu, Xiaorui Zhang, Yang Wang, Minji Guo, Hui Peng, Min Wang, Juan Zhang.VEGFR2-targeted antibody fused with IFNamut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity[J]. Acta Pharmaceutica Sinica B, 2021,11(2): 420-433
2.Zongru Jiang, Li Wang, Xuesong Liu, Cheng Chen, Beilei Wang, Wenliang Wang, Chen Hu, Kailin Yu, Ziping Qi, Qingwang Liu, Aoli Wang, Jing Liu, Guangchen Hong, Wenchao Wang, Qingsong Liu.Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel antiangiogenesis agent[J]. Acta Pharmaceutica Sinica B, 2020,10(3): 488-497
3.Jun Xie, Jiahui Liu, Heng Liu, Shihui Liang, Meigui Lin, Yueyu Gu, Taoli Liu, Dongmei Wang, Hui Ge, Sui-lin Mo.The antitumor effect of tanshinone IIA on antiproliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line[J]. Acta Pharmaceutica Sinica B, 2015,5(6): 554-563
Similar articles: